Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

Exclusion Criteria

• •The drug is contraindicated for medical reasons.
• •Consumption of oral contraceptives, cyclosporine or strong cytochrome p450 (CYP) 3A4 inhibitors, protease inhibitors, erythromycin and azoles.
• •Patients with Type 1 Diabetes Mellitus.
• •Acute or Severe renal dysfunction (glomerular filtration \<30 ml / min / 1.72 m2).
• •History of chronic liver disease or ALT and / or AST ≥ 2 times the upper limit of normal, or GGT ≥3 times the upper limit of normal.
• •Chronic or acute pancreatitis except for acute pancreatitis due to severe hypertriglyceridemia (defined by the presence of triglycerides\> 1000 mg / dl and / or milky plasma, in the absence of other etiological factors of pancreatitis).
• •Patients with active gallbladder disease (defined as acute or chronic gallbladder disorders associated with clinical signs or symptoms).
• •Patient with a history or presence of myopathies.
• •Pregnant or lactating women.
• •Known contraindication or hypersensitivity to the use of any of the components of the investigational drug.
• •The patient is participating in another clinical study involving an investigational treatment or participated in one in the previous 4 weeks.
• •At the medical discretion, a disease that affects the prognosis and prevents outpatient management, for example, but not restricted to: end-stage cancer, kidney, heart, respiratory or liver or mental failure or with scheduled surgical or hospital procedures.
• •Be a patient with a working relationship with the principal investigator or the research center or prisoner.